When a respected provider organization took a stand against the costly new cancer drug, it was both surprising and encouraging
Research says PA can help make treatments safer and more cost-effective, but data sharing must improve
Even today, studies show, only half of treatments are truly based on evidence. Here’s an organization looking to better that share, and it may behoove health plans to help.
The push to integrate health care services and financing may portend a move away from behavioral health carve-outs
As oral chemotherapy becomes more common, so does nonadherence. Cost is only one of the reasons.
The insurer’s tracking effort helps physicians keep tabs on patients who may not be taking their drugs correctly
Case management, prior authorization, and drug utilization control are required
Devices that selectively destroy the renal nerves that affect hypertension have gained international approval, and availability in the United States is not far off
While local governments ponder just what course to take, health plans prepare to grab as much market share as possible
A summary of ECRI Institute’s Emerging Technology Evidence Report